Agreed on all counts. Still, this study is a start for ABBV's plan to move Imbruvica into earlier-stage indications, which is necessary to justify the colossal price of the PCYC deal.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”